To assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral administration of AZD8329 - AZ8329
Study identifier:D2350C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral AZD8329 after Administration of Multiple Ascending Doses in Abdominally Obese but otherwise Healthy Male Subjects
Medical condition
overweight, Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD8329, Placebo
Sex
Male
Actual Enrollment
45
Study type
Interventional
Age
20 Years - 50 Years
Date
Study Start Date: 01 Sept 2010
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: 1 | Drug: Placebo Placebo AZD8329 Oral Solution |
| Experimental: 2 AZD8329 | Drug: AZD8329 AZD8329 Oral Solution 20mg/ml |
Contacts
Investigators
Principal Investigator
Dr. Jan Eriksson
AstraZeneca
